A biopsy is a process to terminate a portion of tissue or a sample of cells from the body to be tried in a laboratory. People may undergo a biopsy if they are experiencing certain signs and symptoms or if the health care provider has identified an area of concern. A biopsy can determine whether an individual has cancer or another condition. Imaging tests, such as CT scans or MRIs, help detect masses or irregular tissue, but they alone can't tell the difference between cancerous cells and cells that aren't cancerous. For most cancers, the only way to make a diagnosis is to conduct a biopsy to gather cells for a more intimate assessment.
China Biopsy Device Market Growth Factors
China's population demographics, disease incidence, and prevalence are the key factors driving the growth of the biopsy device market in China.According to figures from the National Bureau of Statistics (NBS), 1.40967 billion people lived in China in 2023. With 9.02 million births in 2023, the birth rate per thousand people was 6.39.
The NIH publications state that China saw about 4,824,700 new cases of cancer in 2022 (2,533,900 male cases and 2,290,800 female cases).
It also notes that 57.4% of all new cases of cancer were caused by the top five malignancies, which are lung cancer (1,060,600), colorectal cancer (517,100), thyroid cancer (466 100), liver cancer (367,700), and female breast cancer (357,200).
In China, it is projected that 2,574,200 people will lose their lives to cancer in 2022 (1,629,300 men and 944,900 women).
The China biopsy device market is anticipated to be driven by several government and non-government organizations' cancer screening programs and initiatives.
Duke University's project intends to conduct several research studies to identify and develop efficient interventions and policies to help close the disparity in cancer rates in China. The project will also create several cancer advocacy resources to increase awareness of cancer disparities among broader global populations.
To achieve a 46.6 percent overall five-year survival rate among cancer patients by 2030, the Chinese government has released an eight-year action plan for cancer prevention and treatment. The plan states that by 2030, the burden of treating these diseases will be under control, the increasing trend in cancer incidence and death will be moderated, and the capacity for cancer screening, early diagnosis, and treatment will be significantly improved.
The federal Chinese government funds four national cancer screening programs (NCSPs), which serve as the cornerstone of cancer screening in China. China presently includes eight cancer types in its NCSPs: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal.
China Biopsy Device Industry News
The China biopsy device market is segmented into various companies, such as Bio-Rad Laboratories, Exact Sciences (Genomic Health), Becton, Dickinson and Company, Roche Diagnostics, Thermo Fisher Scientific Inc., Qiagen, Biocept, Quest Diagnostics Inc., and NeoGenomics Laboratories.In October 2023 - LUMINELLE announced its decision to expand its global footprint by receiving a patent for its LUMINELLE Bx (Biopsy) System from the China National Intellectual Property Administration.
In September 2023 - Baird Medical Investment Holdings Limited reported that Jiangsu Medical Products Administration, the pharmaceuticals regulatory authority for Jiangsu Province in China, has approved its Single-Use Sterile Biopsy Needle ("SSBN") through its subsidiary Nanjing Changcheng Medical Equipment Co., Ltd. The device, approved on August 30, 2023, and has registration number 20232141234, is used for biopsies of tumors in superficial tissues close to the skin's surface, such as the thyroid, lymph nodes, and breasts.
In July 2023 - The cfDNA liver cancer detection test from Helio Genomics' sister company, Laboratory for Advanced Medicine and Health Group (LAMH), received approval from China's National Medical Products Administration (NMPA). It is stated to be a first in the field of blood-based cancer detection - the first liquid biopsy test authorized by NMPA for liver cancer.
Products - Market is broken up into 4 viewpoints:
1. Needle Based Biopsy Devices2. Biopsy Forceps
3. Localization Wire
4. Others Products
Imaging Technology - Market is broken up into 5 viewpoints:
1. CT scan2. Stereotactic Guided
3. Ultrasound Guided
4. MRI Guided
5. Others
End-User - Market is broken up into 3 viewpoints:
1. Hospital and Clinics2. Diagnostics Laboratories
3. Other
All companies have been covered from 3 viewpoints:
- Overview
- Recent Development
- Revenue
Company Analysis:
1. Bio-Rad Laboratories2. Exact Sciences (Genomic Health)
3. Becton, Dickinson and Company
4. Roche Diagnostics
5. Thermo Fisher Scientific Inc.
6. Qiagen
7. Biocept
8. Quest Diagnostics Inc.
9. NeoGenomics Laboratories
Table of Contents
Companies Mentioned
- Bio-Rad Laboratories
- Exact Sciences (Genomic Health)
- Becton, Dickinson and Company
- Roche Diagnostics
- Thermo Fisher Scientific Inc.
- Qiagen
- Biocept
- Quest Diagnostics Inc.
- NeoGenomics Laboratories
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | May 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 574.31 Million |
| Forecasted Market Value ( USD | $ 1059.41 Million |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | China |
| No. of Companies Mentioned | 9 |
